Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention AstraZeneca, the most common co-covered peer. The 5 average consequence score is below the beat benchmark of 6 in the same window.
Last mentioned: Mar 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention AstraZeneca, the most common co-covered peer. The 5 average consequence score is below the beat benchmark of 6 in the same window. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window. We currently track 1 Biotech story that mention Lorundrostat, all published on March 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Lorundrostat. Shared-story counts are live from our verified record — not editorial picks.
Mineralys Therapeutics (MLYS) reported a narrower-than-expected Q4 2025 loss and confirmed the FDA's acceptance of its New Drug Application for lorundrostat. The company is now pivoting toward commercial readiness for its lead hypertension candidate while maintaining a robust clinical pipeline in chronic kidney disease.
Lorundrostat is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
